Condition category
Cancer
Date applied
06/05/2011
Date assigned
06/05/2011
Last edited
31/08/2017
Prospective/Retrospective
Prospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Contact information

Type

Scientific

Primary contact

Prof Mark Hull

ORCID ID

Contact details

Leeds Institute of Molecular Medicine
Beckett Street
Leeds
LS9 7TF
United Kingdom
-
m.a.hull@leeds.ac.uk

Additional identifiers

EudraCT number

2010-020943-10

ClinicalTrials.gov number

Protocol/serial number

9734

Study information

Scientific title

A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic Evaluation of Aspirin and Fish Oil) polyp prevention trial

Acronym

The seAFOod Polyp Prevention Trial

Study hypothesis

The seAFOod Polyp Prevention Trial is a randomised, double-blind, placebo-controlled 2 x 2 factorial study. The trial has been designed to integrate fully into the screening and surveillance phases of the NHS Bowel Cancer Screening Programme (BCSP) so that participation will not alter routine clinical practice.

Ethics approval

East Midlands - Derby Research Ethics Committee, 24/11/2010, ref: 10/H0405/90

Study design

Randomised; Interventional; Design type: Prevention

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Prevention

Patient information sheet

Patient information can be found at: http://www.seafood-trial.co.uk (under useful documents section)

Condition

Topic: National Cancer Research Network, Oral and Gastrointestinal; Subtopic: Colorectal Cancer, Oral and Gastrointestinal (all Subtopics); Disease: Colon, Gastrointestinal

Intervention

Current interventions as of 29/08/2017:
The trial has a 2x2 factorial design with four treatment arms as follows:
1. EPA-FFA 2g daily or equivalent dose of EPA-TG plus aspirin 300mg once daily
2. EPA-FFA 2g daily or equivalent dose of EPA-TG plus aspirin placebo once daily
3. EPA placebo 2g daily plus aspirin 300mg once daily
4. EPA placebo 2g daily plus aspirin placebo 300mg once daily

Previous interventions:
The trial has a 2x2 factorial design with four treatment arms as follows:
1. EPA as the free fatty acid 1 g twice daily plus aspirin EC 300 mg once daily
2. EPA as the free fatty acid 1 g twice daily plus aspirin placebo once daily
3. EPA placebo twice daily plus aspirin EC 300 mg once daily
4. EPA placebo twice daily plus aspirin placebo once daily

Added 31/08/2017:
To keep power at 80% for the above figures, a simulation using Stata v10 and employing the proposed analysis method indicated that 192 individuals were required per arm (total 768 evaluable ‘high risk’ individuals). In the Trial protocol versions 1-3, a 15% drop-out rate was assumed . However, feedback from BCSP centres and experience from the first few months of the Trial suggested that the drop-out rate of ‘high risk’ BCSP patients would be lower than 15%. Allowance for a 10% drop-out rate increased the sample size to 768/0.9 = 853 individuals.

In October 2014, the trial secured an extension from the EME Programme, for a further 3 years until 31/10/2017. This allowed recruitment to continue to 12/06/2016 at the latest (limited by the shelf-life of EPA-TG approved by the MHRA). Projections based on past trial recruitment predicted that a maximum number of 755 participants might be randomised.

Intervention type

Supplement

Phase

Drug names

Primary outcome measures

The number of patients with one or more adenomas; Timepoint(s): BCSP surveillance colonoscopy at 12 months

Secondary outcome measures

Current secondary outcome measures as of 29/08/2017:
1. Number of adenomas per participant at the first BCSP surveillance colonoscopy (mean adenoma number per participant [MAP])
2. Detection of one or more ‘advanced’ (≥10 mm diameter, high-grade dysplasia or tubulo-villous/villous histology) adenomas at the first BCSP surveillance colonoscopy (advanced ADR [AADR])
3. Number of ‘advanced’ adenomas per participant at the first BCSP surveillance colonoscopy (advanced MAP).
4. Detection of one or more serrated adenomas at the first BCSP surveillance colonoscopy
5. Number of serrated adenomas per participant at the first BCSP surveillance colonoscopy (serrated MAP).
6. The region of the colorectum (right colon - any part of the colon proximal to the splenic flexure; left colon – the rectum and the colon distal to the splenic flexure) that adenomas(total, advanced, serrated) are detected at the first BCSP surveillance colonoscopy
7. Reclassification from ‘high risk’ to ‘intermediate risk’ after the first BCSP surveillance colonoscopy (BCSP risk stratification at the first surveillance colonoscopy states that any individual that does not continue to fulfil ‘high risk’ criteria is classified as ‘intermediate risk’ for further colonoscopic surveillance at three years)
8. Detection of colorectal cancer (CRC) prior to, or at, the first BCSP surveillance colonoscopy
9. Red blood cell (RBC) EPA and rectal EPA levels at baseline, 6 months (RBC only) and 12 months from randomisation
10. Absolute red blood cells (RBC) fatty acid (DHA, AA, EPA/AA ratio) levels and difference from baseline at 6 months and 12 months
11. Dietary fish and other seafood intake at baseline and at the end of the study
12. Rectal mucosal fatty acid (DHA, AA, EPA/AA ratio) levels at surveillance colonoscopy
13. Adverse events, including clinically significant bleeding episodes (haemorrhagic stroke or GI bleeding requiring hospital admission or investigation)

Previous secondary outcome measures:
1. Adverse events, including clinically significant bleeding episodes; Timepoint(s): BCSP surveillance colonoscopy at 12 months
2. The number of 'advanced' adenomas per patient; Timepoint(s): BCSP surveillance colonoscopy at 12 months
3. The number of 'high risk' patients re-classified as 'intermediate risk'; Timepoint(s): BCSP surveillance colonoscopy at 12 months
4. The number of patients with one or more 'advanced' adenomas; Timepoint(s): BCSP surveillance colonoscopy at 12 months
5. The region of the colorectum that adenomas are detected; Timepoint(s): BCSP surveillance colonoscopy at 12 months
6. The total number of adenomas per patient; Timepoint(s): BCSP surveillance colonoscopy at 12 months

Overall trial start date

30/05/2011

Overall trial end date

31/10/2017

Reason abandoned

Eligibility

Participant inclusion criteria

Current inclusion criteria as of 04/07/2013:
Recruitment will be restricted to 55-73 year-old NHS Bowel Cancer Screening Programme (BCSP) patients who have been identified as 'high risk' (5 or more small adenomas or more than 3 adenomas with at least one being >10 mm in diameter) after their first screening colonoscopy by either Faecal Occult Blood test (FOBt) or Flexible Sigmoidoscopy (FS).
Target Gender: Male & Female; Upper Age Limit 73 years; Lower Age Limit 55 years.

Inclusion criteria from 29/05/2012 to 04/07/2013:
Recruitment will be restricted to 60-73 year-old NHS Bowel Cancer Screening Programme (BCSP) patients who have been identified as 'high risk' (5 or more small adenomas or more than 3 adenomas with at least one being >10 mm in diameter) after a single clearance screening colonoscopy.
Target Gender: Male & Female; Upper Age Limit 73 years; Lower Age Limit 60 years.

Original inclusion criteria:
Recruitment will be restricted to 60-75 year-old NHS Bowel Cancer Screening Programme (BCSP) patients who have been identified as 'high risk' (5 or more small adenomas or more than 3 adenomas with at least one being >10 mm in diameter) after a single clearance screening colonoscopy.
Target Gender: Male & Female; Upper Age Limit 75 years; Lower Age Limit 60 years.

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

Planned Sample Size: 755; UK Sample Size: 755

Participant exclusion criteria

Current exclusion criteria as of 29/08/2017:
1. Current exclusion criteria as of 01/10/2012:
2. Requirement for more than one repeat colonoscopy or flexible sigmoidoscopy within the BCSP 3 month screening window
3. Malignant change in an adenoma requiring Colorectal Cancer Multi-disciplinary Team management
4. Regular (>3 doses per week) prescribed or over-the-counter (OTC) aspirin or regular (>3 doses per week) prescribed or OTC non-aspirin non-steroidal anti-inflammatory drug (NSAID) use
5. Aspirin intolerance or hypersensitivity, including aspirin-sensitive asthma
6. Active peptic ulcer disease within 3 months or previous peptic ulcer (not on proton pump inhibitor prophylaxis)
7. Fish or seafood allergy
8. Current or planned regular (>3 doses per week) use of fish oil supplements
9. Known clinical diagnosis or gene carrier of a hereditary colorectal cancer (CRC) predisposition (familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC))
10. Previous or newly diagnosed inflammatory bowel disease
11. Previous or planned colorectal resection
12. Known bleeding diathesis or concomitant warfarin therapy or severe liver impairment
13. Severe liver impairment
14. Severe renal failure (creatinine clearance < 10 ml/min)
15. Current methotrexate use at a weekly dose of 15 mg or more
16. Inability to comply with study procedures and agents
17. Serious medical illness interfering with study participation
18. Failure to give written informed consent

Previous exclusion criteria from 01/10/2012 to 29/08/2017:
1. Requirement for more than one repeat colonoscopy or flexible sigmoidoscopy within the BCSP 3 month screening window
2. Malignant change in an adenoma requiring Colorectal Cancer Multi-disciplinary Team management
3. Regular (>3 doses per week) prescribed or over-the-counter (OTC) aspirin or regular (>3 doses per week) prescribed or OTC non-aspirin non-steroidal anti-inflammatory drug (NSAID) use
4. Aspirin intolerance or hypersensitivity, including aspirin-sensitive asthma
5. Active peptic ulcer disease within 3 months or previous peptic ulcer (not on proton pump inhibitor prophylaxis)
6. Fish or seafood allergy
7. Current or planned regular (>3 doses per week) use of fish oil supplements
8. Known clinical diagnosis or gene carrier of a hereditary colorectal cancer (CRC) predisposition (familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC))
9. Previous or newly diagnosed inflammatory bowel disease
10. Previous or planned colorectal resection
11. Known bleeding diathesis or concomitant warfarin therapy or severe liver impairment
12. Severe renal failure (creatinine clearance < 10 ml/min)
13. Current methotrexate use at a weekly dose of 15 mg or more
14. Inability to comply with study procedures and agents
15. Serious medical illness interfering with study participation
16. Failure to give written informed consent

Previous exclusion criteria from 29/05/2012 to 01/10/2012:
1. Need for repeat colonoscopy or flexible sigmoidoscopy to check for adenoma excision within a 3 month window

Previous exclusion criteria
1. Need for repeat colonoscopy or flexible sigmoidoscopy to check for adenoma excision within a 3 month window
2. Malignant change in an adenoma requiring Colorectal Cancer Multi-disciplinary Team management
3. Regular (>3 doses per week) prescribed aspirin or regular (>3 doses per week) prescribed nonaspirin nonsteroidal antiinflammatory drug (NSAID) use
4. Aspirin intolerance or hypersensitivity, including aspirin-sensitive asthma
5. Active peptic ulcer disease within 3 months or previous peptic ulcer (not on proton pump inhibitor prophylaxis)
6. Fish or seafood allergy
7. Current or planned regular (>3 doses per week) use of fish oil supplements
8. Known clinical diagnosis or gene carrier of a hereditary colorectal cancer (CRC) predisposition (familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC))
9. Previous or newly diagnosed inflammatory bowel disease
10. Previous or planned colorectal resection
11. Known bleeding diathesis or concomitant warfarin therapy or severe liver impairment
12. Severe renal failure (creatinine clearance < 10 ml/min)
13. Current methotrexate use at a weekly dose of 15 mg or more
14. Inability to comply with study procedures and agents
15. Serious medical illness interfering with study participation
16. Failure to give written informed consent

Recruitment start date

11/11/2011

Recruitment end date

12/06/2016

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Participating centres across England, go to http://www.nottingham.ac.uk/mczseafood/centres.html for a list of sites
-
United Kingdom

Sponsor information

Organisation

University of Leeds (UK)

Sponsor details

Faculty of Medicine and Health
Joint Leeds Sponsor Office
Research & Innovation
34 Hyde Terrace
Leeds
LS2 9LN
United Kingdom

Sponsor type

University/education

Website

Funders

Funder type

Government

Funder name

Efficacy and Mechanism Evaluation Programme

Alternative name(s)

NIHR Efficacy and Mechanism Evaluation Programme, EME

Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The trialists are currently working on a dissemination plan and will share this when it is finalised.

IPD sharing statement
The data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date

31/10/2018

Participant level data

To be made available at a later date

Results - basic reporting

Publication summary

2013 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/23895505

Publication citations

Additional files

Editorial Notes

31/08/2017: Publication and dissemination plan and IPD sharing statement added. 29/08/2017: The following changes were made to the trial record: 1. The recruitment end date was changed from 30/06/2016 to 12/06/2016. 2. The overall trial end date was changed from 31/07/2017 to 31/10/2017. 3. The target number of participants was changed from 904 to 755. 01/05/2015: The overall end date was changed from 29/05/2013 to 31/07/2017.